With a new CEO, a new subsidiary, a newly approved gene therapy and three R&D centers under construction on three different continents, change is coming fast for CSL Limited.

CSL Head of R&D and Chief Medical Officer Bill Mezzanotte is interviewed in the Australian Financial Review (Subscription Required)

CSL is taking action by setting 2030 carbon targets, CSL’s Chief Financial Officer says.

CSL is building the foundations for decentralised trials to be a core part of its research and development efforts within this decade, speeding up clinical development and opening up trials to more patients. (Subscription Required)

Lean into the momentum and innovation that the global pandemic inspired, CSL CEO Paul Perreault told attendees of The Economic Times Global Business Summit.

Leaders in science convened to discuss the most pressing topics in biotech, medicine and policy at the 2021 STAT Summit.

The CFO of global biotech company CSL, Joy Linton, has reached great heights by embracing ambiguity and saying yes to challenges.

CSL’s Chief Financial Officer Joy Linton talks to Business Chicks about playing the career long game.